Lung Cancer Xenograft Models:

Subcutaneous, Orthotopic, And Metastatic Xenograft Tumor Models

By Altogen Labs, 11200 Menchaca Road, Suite 203, Austin, TX 78748
Phone: (512) 433-6177 | Email: info@altogenlabs.com

Table of Contents

Xenograft and Allograft Models Advance Preclinical Research in Lung Cancer

Lung cancer remains the leading cause of cancer-related mortality worldwide, characterized by high incidence rates, frequent late-stage diagnoses, and poor long-term survival outcomes. Despite considerable advances in diagnostic imaging, molecular profiling, and targeted therapies, therapeutic resistance and tumor heterogeneity continue to challenge clinical management. The development of reliable preclinical models that recapitulate the complexity of human lung tumors is critical for understanding oncogenic mechanisms, evaluating therapeutic efficacy, and identifying novel biomarkers. Among the array of available models, xenografts and allografts have emerged as indispensable tools for bridging the gap between *in vitro* studies and clinical applications. However, despite their widespread use, current xenograft models often fail to fully capture the nuances of the tumor microenvironment, especially regarding immune interactions and metastatic behavior, thereby limiting translational relevance.

The integration of xenograft and allograft models in lung cancer research serves multiple objectives: to recapitulate tumor architecture and progression, to evaluate pharmacodynamic and pharmacokinetic properties of candidate therapeutics, and to facilitate mechanistic studies of tumor biology. Xenograft models, typically established by engrafting human tumor cells into immunocompromised mice, provide a reproducible and scalable platform for drug testing, while syngeneic allografts, involving murine tumor cells implanted into immunocompetent hosts, allow for interrogation of tumor-immune interactions. These models collectively enable the investigation of both intrinsic tumor features and extrinsic modulatory factors. The rationale behind employing such models lies in their ability to simulate tumor growth dynamics, clonal evolution, and therapeutic response in a physiologically relevant *in vivo* context. This research contributes to the broader academic discourse by offering insights into mechanisms of resistance, metastatic dissemination, and therapeutic vulnerability. As the field advances toward precision medicine, the refinement of xenograft and allograft systems will be essential to enhancing preclinical predictive accuracy and ultimately improving clinical outcomes in lung cancer patients.

Subcutaneous Lung Cancer Xenograft Models

Subcutaneous xenograft transplantation remains a foundational technique in preclinical cancer research, offering a reproducible and accessible method for evaluating tumorigenic potential, therapeutic efficacy, and molecular responses *in vivo*. This model involves the implantation of human or murine tumor cells into the subcutaneous tissue, typically in the flank region, enabling straightforward monitoring of tumor growth kinetics and facilitating longitudinal pharmacological studies. While the method lacks the microenvironmental fidelity of orthotopic or metastatic models, its logistical simplicity, high tumor take rate, and compatibility with diverse analytical endpoints have made it a mainstay in translational oncology studies.

In lung cancer research, a wide array of human-derived cell lines has been utilized in subcutaneous xenograft systems to investigate distinct histological and molecular subtypes. For instance, A549, H460, and H1155 have been extensively used to model non-small cell lung cancer (NSCLC), particularly in studies examining KRAS mutations and resistance to cytotoxic agents. H1975, H1993, and HCC827, which harbor mutations or amplifications in the EGFR and MET signaling pathways, have served as critical tools in the evaluation of targeted therapies and mechanisms of acquired resistance. Small cell lung cancer (SCLC) has been modeled using cell lines such as H526 and DMS273, supporting studies into neuroendocrine differentiation and chemotherapeutic responsiveness. Other NSCLC lines, including Calu-3, Calu-6, H226, H1703, and H1155, have further enriched the field by enabling comparative analyses across histotypes and driver alterations. Additionally, the murine Lewis lung carcinoma cell line LL2 has been employed in immunocompetent models, offering insights into immune responses and tumor-host interactions. Collectively, subcutaneous xenograft models incorporating these diverse cell lines have provided robust platforms for elucidating lung cancer biology, identifying candidate therapeutics, and generating preclinical data to guide clinical trial design.

Despite their utility, subcutaneous models are not without limitations. They often fail to replicate the complex stromal, vascular, and immune interactions characteristic of native pulmonary tissue. As such, while these models yield valuable quantitative data and facilitate high-throughput screening, their findings must be interpreted in conjunction with orthotopic, metastatic, or humanized systems to ensure translational relevance. Future efforts should prioritize integrating subcutaneous xenografts with complementary platforms and advanced imaging or biomarker strategies to enhance their predictive value and mechanistic insight. By doing so, the field can continue to refine its experimental toolkit and strengthen the bridge between preclinical discovery and clinical application in lung cancer research.

Orthotopic Lung Cancer Xenograft Models

Orthotopic xenograft transplantation represents a critical advancement in the development of physiologically relevant cancer models. By implanting tumor cells into the organ of origin, this approach enables the recapitulation of the native tumor microenvironment, including tissue-specific architecture, stromal composition, and local signaling cues that influence tumor progression, invasion, and response to therapy. In lung cancer research, orthotopic models have demonstrated particular value in investigating metastatic spread, drug distribution, and immune modulation, thereby offering insights that are not readily attainable through subcutaneous transplantation.

Several human and murine cell lines have been successfully adapted for orthotopic lung cancer modeling, enabling comprehensive investigations into tumor behavior within the pulmonary niche. The large cell line H460 and the small cell line H526 have been employed to evaluate growth patterns, angiogenesis, and therapeutic responses in orthotopically implanted models. DMS273, another small cell line, has supported studies focused on neuroendocrine phenotypes and chemoresistance mechanisms. Non-small cell lung cancer lines such as H1155, H1703, and H1993 have allowed for mechanistic interrogation of signaling pathways including PI3K, MET, and PDGFR within the lung microenvironment. Importantly, the murine LL2 cell line has been widely used in syngeneic orthotopic models to explore tumor-immune dynamics in immunocompetent hosts. These models collectively provide a versatile framework to assess lung cancer biology under conditions that more accurately reflect the clinical setting.

While orthotopic transplantation introduces technical complexity and limits real-time tumor monitoring due to the internal anatomical location, it offers unparalleled fidelity in modeling disease progression and therapeutic resistance. Advances in imaging modalities such as bioluminescence and micro-CT have partially mitigated these challenges by enabling non-invasive tracking of tumor growth. Future work should continue refining surgical techniques, integrating immune-competent systems, and employing molecular characterization to enhance model reproducibility and translational relevance. Through such efforts, orthotopic xenograft transplantation will remain an essential component of lung cancer research, bridging preclinical studies with clinical realities and strengthening the scientific foundation for therapeutic innovation.

Metastatic Lung Cancer Xenograft Models

Metastatic xenograft transplantation models have become increasingly important for studying the mechanisms underlying cancer dissemination, colonization, and resistance to systemic therapies. Unlike subcutaneous or orthotopic models, metastatic models are designed to recapitulate the multistep process of metastasis, including invasion, intravasation, circulation, extravasation, and outgrowth at secondary sites. These models are typically established through intravenous, intracardiac, or intratracheal injection of tumor cells, allowing researchers to observe spontaneous or organ-specific metastatic patterns. Given that metastasis is responsible for many cancer-related deaths, these models provide essential insights into late-stage disease biology and therapeutic vulnerabilities that are often undetectable in primary tumor-focused studies.

Several lung cancer cell lines have been utilized to establish robust metastatic xenograft models with reproducible patterns of dissemination. The A549 cell line, derived from human alveolar basal epithelial carcinoma, has been widely employed in tail vein injection models to study pulmonary metastasis and response to chemotherapeutic agents. DMS273, a small cell lung cancer line, exhibits metastatic potential when introduced via the venous circulation and has supported investigations into neuroendocrine differentiation and metastatic tropism. H1993, which overexpresses MET and represents a model of MET-amplified non-small cell lung cancer, is frequently used in experimental metastasis assays to explore receptor tyrosine kinase–driven dissemination and therapeutic resistance. Similarly, HCC827, characterized by EGFR mutations, has contributed to studies on the metastatic response to tyrosine kinase inhibitors and has facilitated the evaluation of acquired resistance mechanisms in distal organs. Together, these cell lines have enabled rigorous interrogation of molecular drivers, metastatic niches, and pharmacologic efficacy across diverse metastatic contexts.

Despite the power of metastatic xenograft models to mimic advanced disease progression, several challenges remain. Variability in metastatic efficiency, lack of immune components in immunodeficient hosts, and limited ability to model spontaneous metastasis from a primary tumor site constrain their translational relevance. Ongoing efforts to incorporate humanized immune systems, improve imaging technologies for real-time metastasis tracking, and develop co-clinical trial frameworks are crucial for enhancing the fidelity of these models. As such, metastatic xenograft transplantation continues to serve as a vital tool in lung cancer research, offering a platform to investigate the biological complexity of metastatic disease and inform the development of targeted therapies that address the most lethal phase of tumor evolution.

Characterization and Preclinical Application of the A549 Xenograft Model in Lung Cancer Research



The A549 xenograft model developed by Altogen Labs represents a widely validated platform for investigating non-small cell lung cancer (NSCLC), particularly pulmonary adenocarcinoma. Originating from a tumor isolated in 1972 from a 58-year-old male patient, the A549 cell line is a foundational tool in preclinical research due to its capacity to replicate tumor growth, spontaneous metastasis, and responsiveness to pharmacological agents. This model is employed in both subcutaneous and metastatic settings and supports the evaluation of therapeutic efficacy, tumor biology, and drug resistance mechanisms in a physiologically relevant context. Altogen Labs provides a robust subcutaneous A549 xenograft model in which one million viable A549 cells, suspended in Matrigel, are injected into the hind limbs of athymic BALB/c or NOD/SCID mice. Tumor progression is monitored using caliper measurements, and once volumes reach between 75 and 150 mm^3, test subjects are assigned to treatment cohorts. Tumors are subsequently excised and analyzed through histology, gene expression studies, and molecular assays such as RNA preservation or snap freezing. The model supports comprehensive tumor growth assessment and offers reliable endpoints for evaluating therapeutic intervention.

Additional applications include the metastatic A549 xenograft model, which introduces cells via orthotopic lung implantation or tail vein injection to study dissemination to distal organs such as the liver, bones, and brain. The orthotopic version is especially valuable for simulating clinical lung cancer progression, achieving a 90 percent tumor formation rate and universal metastatic spread with a median survival time of approximately 30 days. Imaging techniques such as spiral CT are employed to monitor tumor burden and therapeutic response dynamically. The A549 model has been used in numerous case studies. For example, paclitaxel administered at 20 mg/kg demonstrated effective tumor suppression in subcutaneous models. Investigations with betulin-aldehyde revealed that autophagic activity increased in a concentration-dependent manner, suppressing oncogenic behavior in A549 cells. Studies involving CD34-positive humanized mice showed that tumor growth is influenced by immune system engagement, with slower proliferation observed in immunocompetent hosts. Furthermore, co-culturing mesenchymal stem cells with A549 cells resulted in elevated proto-oncogene expression, raising important considerations for regenerative therapies in oncologic environments.

Altogen Labs offers this in-house validated A549 xenograft model as part of its suite of preclinical oncology services. The model supports various routes of drug administration including intravenous, subcutaneous, intratracheal, oral, and intratumoral injection. It is also compatible with advanced methodologies such as microinjection, pump-controlled infusion, immunohistochemistry, and ADME analysis. Applications include toxicity evaluation, survival analysis, and the use of standard chemotherapy compounds as positive controls. This validated A549 xenograft model is available through Altogen Labs, a preclinical contract research organization specializing in oncology model development. Detailed information, including a downloadable technical datasheet, can be accessed at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/a549-xenograft-model/. The complete technical PDF describing the A549 model is available at https://altogenlabs.com/A549XenograftModel.pdf.

Characterization and Preclinical Application of the Calu-3 Xenograft Model in Lung Cancer Research



The Calu-3 xenograft model, developed and validated by Altogen Labs, serves as a clinically relevant preclinical system for studying non-small cell lung cancer (NSCLC), particularly adenocarcinoma. Derived in 1975 from the pleural effusion of a 25-year-old male patient, Calu-3 cells exhibit a well-differentiated epithelial morphology and are widely used in studies of tumor biology, therapeutic resistance, and drug efficacy. Their capacity to form polarized monolayers enhances their utility for modeling respiratory epithelial barriers and supports their role in evaluating targeted therapies and anti-angiogenic strategies.

In the validated protocol employed by Altogen Labs, exponentially growing Calu-3 cells are harvested, assessed for viability exceeding 99 percent using the MTT assay, and suspended in Matrigel at a concentration of one million cells per 200 microliters. These are subcutaneously injected into the hind flanks of immunocompromised nu/nu or BALB/c mice aged 10 to 11 weeks. Tumor development is tracked using caliper measurements until volumes reach 90 to 140 mm³, at which point subjects are randomized into treatment arms. Tumor volume and body weight are recorded routinely. Upon reaching terminal endpoints or maximum permissible tumor burden, animals are euthanized, and tumors are excised, weighed, imaged, and preserved for histological and molecular analysis.

The subcutaneous Calu-3 xenograft model provides a reproducible and straightforward *in vivo* platform for evaluating lung cancer therapies, including chemotherapeutics, EGFR inhibitors, and anti-angiogenic compounds. The model has demonstrated robust utility in preclinical studies such as the investigation of cediranib, where Calu-3 xenografts exhibited significant sensitivity to VEGFR inhibition. Cediranib treatment led to vascular disruption, increased tumor hypoxia, and substantial tumor regression within 24 hours. These outcomes highlight the relevance of the Calu-3 model for evaluating agents targeting tumor vasculature and stromal architecture. Dynamic contrast-enhanced MRI was proposed as a non-invasive modality to predict therapeutic response based on vascular phenotype.

Molecularly, Calu-3 cells are characterized by ERBB2 (HER2) gene amplification and sensitivity to EGFR tyrosine kinase inhibitors, including erlotinib. These features define the oncogenic landscape of this model and make it especially useful for testing HER2-driven and EGFR-targeted therapies. The Calu-3 model also supports advanced pharmacological evaluations, including tumor growth delay and inhibition assessments, as well as comprehensive analyses such as blood chemistry, toxicity, immunohistochemistry, and systemic response evaluations.

Comprehensive information on the Calu-3 xenograft model is available on the Altogen Labs website at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/calu-3-xenograft-model/. The complete technical PDF describing the Calu-3 model is available at https://altogenlabs.com/Calu3XenograftModel.pdf.



The Calu-6 xenograft model offered by Altogen Labs provides a rigorously validated preclinical platform for investigating non-small cell lung cancer (NSCLC), with relevance to tumors exhibiting anaplastic and KRAS-driven phenotypes. Derived from the lung tissue of a 61-year-old female patient with anaplastic carcinoma, the Calu-6 cell line retains key epithelial characteristics and is widely used in oncology research to evaluate tumorigenic behavior, drug resistance, and therapeutic efficacy. Its adaptability to long-term *in vitro* and *in vivo* studies makes it particularly useful for evaluating chemotherapeutics, radiation sensitizers, and targeted agents, as well as for the development and testing of aerosolized therapies due to its relevance in modeling pulmonary epithelium.

In the standard protocol established at Altogen Labs, Calu-6 cells are cultured under exponential growth conditions and assessed for viability using the trypan blue exclusion assay, ensuring a minimum of 99 percent viable cells. One million cells, suspended in 100 to 150 microliters of Matrigel, are subcutaneously injected into the hind leg of athymic BALB/c mice aged 11 to 12 weeks. Tumor development is monitored via palpation and digital caliper measurement. Once tumors reach 100 to 120 mm³, animals are randomized into treatment cohorts. Experimental endpoints include daily tumor volume measurements and eventual necropsy at tumor volumes nearing 2,000 mm³. Tumors are excised, digitally imaged, and processed for histological, molecular, or genomic analyses using RNAlater stabilization or cryopreservation methods.

The subcutaneous Calu-6 xenograft model is a widely adopted *in vivo* tool for assessing lung cancer progression and drug response. It enables straightforward tumor monitoring and is used to evaluate not only efficacy, but also pharmacokinetics, systemic toxicity, and survival outcomes. In case studies, Calu-6 xenografts have demonstrated distinct pharmacological behavior. One study published in *Lung Cancer* showed that cediranib, a VEGFR tyrosine kinase inhibitor, was significantly less effective in Calu-6 xenografts compared to Calu-3 models, indicating a reduced sensitivity due to the tumor vessel phenotype. Another study published in *Molecular Cancer* reported that motesanib, a VEGF receptor antagonist, exhibited only modest efficacy in Calu-6 xenografts as a monotherapy, but tumor inhibition was significantly enhanced when combined with cisplatin. Calu-6 cells are known for harboring oncogenic KRAS mutations, which promote aggressive tumor behavior and confer resistance to apoptosis. This makes the model highly relevant for studies focused on oncogene-targeted therapies and resistance mechanisms.

Learn more about the validated Calu-6 xenograft model and request technical documentation specifically at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/calu-6-xenograft-model/. The complete technical PDF describing the Calu-6 model is available at https://altogenlabs.com/Calu-6XenograftModel.pdf.

Characterization and Preclinical Application of the DMS273 Xenograft Model in Lung Cancer Research



The DMS273 xenograft model, developed and validated by Altogen Labs, serves as a robust preclinical platform for studying small cell lung cancer (SCLC), particularly aggressive and treatment-resistant forms. Derived in 1978 from a pleural effusion sample of a 50-year-old female patient who relapsed after chemotherapy and radiation, the DMS273 cell line exhibits high tumorigenicity and expresses retinoblastoma protein, making it highly suitable for investigating tumor biology, drug resistance mechanisms, and novel therapeutic strategies. This model enables comprehensive evaluation of tumor progression, metastasis, and therapeutic efficacy *in vivo*.

Altogen Labs offers a subcutaneous, orthotopic, and metastatic DMS273 xenograft model. In the subcutaneous model, one million viable DMS273 cells are injected with Matrigel into the flank of immunocompromised mice. Tumors are monitored until they reach 50–100 mm³, at which point animals are randomized into treatment cohorts. Tumor volumes and body weights are recorded regularly until endpoint criteria are met. Tissues are collected post-necropsy for histological, molecular, and genomic analyses. The model supports evaluation of tumor growth inhibition, survival outcomes, and drug pharmacodynamics through flexible dosing regimens and various administration routes.

The orthotopic and metastatic variants of this model provide physiologically relevant systems for assessing tumor growth within the pulmonary microenvironment and metastatic spread to distant organs including bone, brain, and kidney. Studies using GFP-labeled DMS273 sublines, such as the highly metastatic G3H, have demonstrated the involvement of the HGF/MET signaling axis in promoting invasiveness. MET inhibition significantly reduced metastasis, affirming the utility of this model for evaluating anti-metastatic therapies. The DMS273 model has also shown sensitivity to novel therapeutics such as TEM8-targeting antibody-drug conjugates (ADC), which achieved tumor regression with minimal toxicity. Additionally, metabolic studies have identified RRM1 and deoxyribonucleotide biosynthesis as critical vulnerabilities, supporting targeted drug development.

DMS273 tumors exhibit activation of oncogenic drivers including c-MYC and autocrine HGF/MET signaling, contributing to rapid proliferation, therapeutic resistance, and metastatic dissemination. The model accommodates detailed tumor analysis, including immunohistochemistry, blood chemistry, genotoxicity, and advanced imaging. Alternative engraftment techniques, such as tail vein and mammary fat pad injection, allow for the investigation of systemic disease progression. A positive control group using cyclophosphamide further enhances experimental reliability.

Comprehensive information about the validated DMS273 xenograft model is available on the Altogen Labs website at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/dms273-xenograft-model/. The complete technical PDF describing the complete DMS273 model is also available at https://altogenlabs.com/DMS273XenograftModel.pdf.

Characterization and Preclinical Application of the NCI-H226 Xenograft Model in Lung Cancer Research



The NCI-H226 xenograft model, developed and validated by Altogen Labs, provides a highly relevant preclinical system for evaluating novel therapies targeting thoracic malignancies, including lung squamous cell carcinoma and mesothelioma. Originating from the pleural effusion of a patient with mesothelioma, the NCI-H226 cell line is extensively used in oncology research due to its epithelial phenotype and tumorigenic potential. This model enables researchers to study tumor growth dynamics, angiogenesis, drug resistance, and molecular signaling pathways in a controlled *in vivo* setting, supporting the advancement of precision therapies for aggressive lung cancers.

At Altogen Labs, NCI-H226 cells are cultured under exponential growth conditions and harvested using trypsin-EDTA. One million viable cells are suspended in 150 microliters of a 50 percent Matrigel solution and injected subcutaneously into the hind leg of athymic BALB/c mice. Tumor growth is monitored until volumes reach 100–150 mm³, at which point mice are randomized into treatment groups. Tumor volume and body weight are recorded regularly, and upon study completion, tumors are excised, imaged, weighed, and preserved by snap freezing or formalin fixation for histological analysis. The model supports a range of experimental endpoints including tumor growth inhibition, survival studies, and immunohistochemical profiling.

This xenograft model has demonstrated strong utility in studies of tumorigenic signaling. For instance, NCI-H226 cells were used to investigate the oncogenic role of tastin, whose suppression significantly reduced tumor proliferation and invasion through downregulation of the ErbB4-PI3K/AKT and ERK1/2 pathways. In another study, NCI-H226 cells exhibited notable sensitivity to GSK3052230, an FGF ligand trap that inhibits FGFR-mediated autocrine signaling, resulting in marked tumor growth inhibition and reduced vascular density. Additionally, the EIF4G1 protein was shown to regulate cell cycle progression and tumorigenicity in NCI-H226 cells via the AKT/mTOR pathway, highlighting its potential as a therapeutic target and prognostic marker.

The NCI-H226 xenograft model offers extensive experimental flexibility. At Altogen Labs, researchers can tailor studies to include intravenous, intratumoral, oral, intratracheal, and continuous infusion dosing, as well as advanced techniques such as micro-injection and whole-body fluorescence imaging. Orthotopic and metastatic variants using tail vein or ventricular injection are also supported. Additional studies can include toxicity assessments, blood chemistry analysis, necropsy evaluations, and comparative efficacy using standard agents such as cyclophosphamide.

Detailed information regarding the NCI-H226 xenograft model is available on the Altogen Labs website at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/nci-h226-xenograft-model/. The complete technical PDF describing the NCI-H226 model is available at https://altogenlabs.com/NCI-H226XenograftModel.pdf.

Characterization and Preclinical Application of the H460 Xenograft Model in Lung Cancer Research



The H460 xenograft model, validated by Altogen Labs, offers a well-characterized and reproducible platform for preclinical studies of large cell lung carcinoma (LCLC), a subtype of non-small cell lung cancer (NSCLC) known for its aggressive progression and limited treatment options. Derived from a male patient in 1982, the NCI-H460 cell line exhibits epithelial morphology and expresses functional p53 mRNA while lacking neurofilament triplet proteins, indicating a non-neuronal lineage. Its stable growth kinetics and responsiveness to therapeutic modulation make it ideal for evaluating drug efficacy, mechanisms of resistance, and molecular signaling pathways relevant to lung cancer progression.

In Altogen Labs' validated study protocol, exponentially growing H460 cells are harvested, assessed for at least 98 percent viability, and suspended in Matrigel for subcutaneous injection into immunocompromised NOD/SCID or BALB/c mice. Each mouse receives one million cells in a 0.1-0.2 mL volume injected into the hind leg. Tumor volumes are measured using digital calipers, and upon reaching 80-120 mm³, mice are randomized into treatment groups. Tumors are monitored daily, and mice are euthanized at endpoint volumes of 2,000 mm³. Post-study necropsy includes tumor excision, weighing, imaging, and tissue preservation for downstream histological, molecular, or genomic analyses.

The H460 model supports both subcutaneous and orthotopic xenograft applications. Subcutaneous tumors provide reliable monitoring for tumor growth delay and inhibition studies, while orthotopic models involve direct lung implantation to better replicate the tumor microenvironment and metastatic behavior. *In vivo* imaging modalities, such as fluorescence or bioluminescence, enhance real-time monitoring. The H460 model is known for its high tumorigenicity and enrichment inside population (SP) cancer stem cells, which are characterized by self-renewal capacity, high expression of ABCG2 and SMO, and activation of the Hedgehog signaling pathway. These features make H460 suitable for evaluating both standard treatments and novel targeted therapies.

Case studies involving this model have demonstrated significant findings. Asperolide A, a marine-derived compound, was shown to suppress tumor growth by inducing G2/M cell cycle arrest via stabilization of the p53-p21 axis and Ras/ERK pathway modulation. These mechanistic insights illustrate the utility of the H460 model for dissecting oncogenic signaling and validating therapeutic candidates with reduced toxicity profiles.

More information on the validated H460 xenograft model can be found specifically at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/h460-xenograft-model/. The complete technical PDF describing the H460 model is available at https://altogenlabs.com/H460XenograftModel.pdf.

Characterization and Preclinical Application of the H526 Xenograft Model in Lung Cancer Research



The H526 xenograft model, validated by Altogen Labs, is a preclinical system optimized for investigating small cell lung cancer (SCLC), a highly aggressive malignancy with rapid tumor progression and early metastatic potential. Derived from a 55-year-old male patient, the NCI-H526 cell line is characterized by a suspension morphology and expresses key neuroendocrine markers such as chromogranin A and synaptophysin. The cell line also carries typical genetic alterations found in SCLC, including TP53 and RB1 mutations, making it a clinically relevant model for studying tumor biology, resistance mechanisms, and therapeutic efficacy.

Altogen Labs offers both subcutaneous and orthotopic H526 xenograft models. In the subcutaneous model, one million viable H526 cells are suspended in 150 to 200 microliters of a Matrigel-based matrix and injected into the flank of immunodeficient mice. Tumor establishment is monitored until reaching 100 to 150 mm³, after which mice are randomized into treatment groups. Tumor volumes and body weights are recorded throughout the study, and endpoint analyses include tumor excision, weighing, digital imaging, and preservation for histological and molecular assessments. The orthotopic variant involves direct implantation of H526 cells into the lung, offering a more physiologically relevant model for studying local invasion, stromal interactions, and metastatic dissemination.

Studies utilizing the H526 model have demonstrated significant findings in the context of novel therapeutic agents. One investigation evaluated 4C9-DM1, a c-Kit-targeting antibody-drug conjugate, which exhibited strong internalization and potent cytotoxicity in H526 cells. When combined with carboplatin or lurbinectedin, the treatment led to over 85 percent tumor growth inhibition, supporting its development for c-Kit-positive SCLC. Another study showed that inhibiting the PI3K/BMX pathway sensitized H526 tumors to BH3 mimetics such as ABT-737 and Navitoclax, highlighting the importance of survival signaling in chemoresistance. The model has also been used to compare cisplatin and oxaliplatin responses, with findings indicating differential stress pathway activation and implications for therapeutic resistance.

H526 cells possess a tumor-initiating side population capable of reconstituting tumors from as few as 50 cells, and they express multidrug resistance transporters such as ABCG2, making them particularly useful for investigating stemness and drug resistance in SCLC. Oncogenic pathway activation, including MYC, WNT, and Notch signaling, further enhances their utility in mechanistic studies and biomarker discovery. At Altogen Labs, the H526 model supports flexible dosing strategies and administration routes including intravenous, intratracheal, intratumoral, oral, and advanced methods such as pump-controlled microinjection. Additional endpoints include tumor growth delay and inhibition analyses, immunohistochemistry, survival studies, toxicity assessments, and advanced imaging such as whole-body fluorescence visualization.

More information on the H526 xenograft model is available on the Altogen Labs website at. The complete technical PDF describing the H526 model is available at https://altogenlabs.com/H526XenograftModel.pdf.

Characterization and Preclinical Application of the H1155 Xenograft Model in Lung Cancer Research



The H1155 xenograft model developed by Altogen Labs is a validated and robust preclinical platform for studying non-small cell lung cancer (NSCLC), particularly aggressive and poorly differentiated subtypes. Derived from the lung tissue of a 36-year-old male patient, the NCI-H1155 cell line exhibits epithelial morphology and is widely utilized to investigate NSCLC tumor biology, drug resistance, and therapeutic responses. Its unique gene expression profile, including low VEGF-C levels and a non-lymphangiogenic phenotype, makes it particularly suitable for studies exploring tumor progression, invasion, and personalized medicine strategies in lung cancer.

Altogen Labs offers both subcutaneous and orthotopic xenograft models using H1155 cells. In the subcutaneous protocol, one million viable cells are suspended in Matrigel and injected into the flank of immunocompromised NOD/SCID or BALB/c mice. Tumors are measured using digital calipers until reaching 50–150 mm³, at which point treatment groups are initiated. Mice are monitored for tumor growth, body weight, and general health throughout the study. Upon completion, tissues are harvested and preserved for histological, molecular, or genomic analyses using snap freezing, RNA-later stabilization, or fixation protocols. Orthotopic implantation involves delivery of H1155 cells directly into the lung, providing a more physiologically relevant environment to evaluate metastasis and therapeutic efficacy using advanced imaging modalities such as PET-CT or bioluminescence.

Recent studies have leveraged the H1155 model to evaluate targeted therapies. A fully human CXCR4 monoclonal antibody demonstrated strong diagnostic utility and therapeutic efficacy in H1155 tumors overexpressing CXCR4, with tumor growth suppression observed *in vivo*. Conversely, tumors with low CXCR4 expression showed minimal response, underscoring the model's relevance for biomarker-driven precision oncology. The H1155 model has also been instrumental in characterizing taxol resistance, revealing cell-specific genetic dependencies that do not extend to other NSCLC lines, further emphasizing its unique tumor biology.

Altogen Labs supports comprehensive customization of study design, including tumor growth delay (TGD) and tumor growth inhibition (TGI) assessments, as well as diverse administration routes such as intravenous, subcutaneous, intratracheal, oral, and micro-injection methods. Additional options include orthotopic transplantation, metastatic models via tail vein or ventricular injection, immunohistochemistry, ADME analysis, toxicity profiling, survival studies, and real-time tumor visualization with whole-body fluorescence imaging. A positive control group using cyclophosphamide enhances benchmarking of therapeutic efficacy.

More information about the H1155 xenograft model can be found specifically at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/h1155-xenograft-model/. The complete technical PDF describing the H1155 model is available at https://altogenlabs.com/H1155XenograftModel.pdf.

Characterization and Preclinical Application of the H1703 Xenograft Model in Lung Cancer Research



The H1703 xenograft model, developed and validated by Altogen Labs, offers a highly relevant preclinical platform for studying non-small cell lung cancer (NSCLC), specifically the squamous cell carcinoma subtype. The NCI-H1703 cell line, derived from a stage I squamous carcinoma in a 54-year-old male smoker, exhibits hallmark features of smoking-associated lung cancer, including PDGFRα amplification and TP53 mutation. This model supports investigations into receptor tyrosine kinase signaling, oncogenic transformation, and therapeutic resistance, providing a critical resource for evaluating novel targeted therapies and oxidative stress-related vulnerabilities in squamous NSCLC.

Altogen Labs maintains H1703 cells under exponential growth prior to xenotransplantation. A suspension of 2 to 5 million cells in a 1:1 mixture of complete media and Matrigel is subcutaneously injected into the flanks of immunodeficient mice. Tumor growth is monitored bi-weekly with calipers, reaching a target volume of 100–150 mm³ before randomization into treatment cohorts. Tumors may also be grown to approximately 300 mm³ for imaging and biodistribution studies. During the study, tumor size, body weight, and health indicators are recorded. Upon completion, tumors are excised, weighed, imaged, and preserved for histological, molecular, or biochemical analysis.

Two recent studies underscore the utility of the H1703 model. The first, published in Cancer Discovery, demonstrated that DDR2 mutations in squamous NSCLC promote tumorigenesis and can be therapeutically targeted by dasatinib. *In vivo*, H1703 xenografts treated with dasatinib exhibited marked tumor growth inhibition, with additional efficacy observed when combined with erlotinib. A second study in The Journal of Pharmacology and Experimental Therapeutics showed that JS-K, a nitric oxide-releasing prodrug, suppressed H1703 tumor growth by 75 percent. The compound's activity was linked to elevated reactive oxygen and nitrogen species, mitochondrial damage, and apoptosis. Resistance correlated with PRX1 levels, positioning this enzyme as a potential biomarker for treatment stratification.

The H1703 model enables both subcutaneous and orthotopic transplantation. Subcutaneous models facilitate straightforward tumor monitoring and longitudinal drug efficacy studies, while orthotopic implantation into the lung offers a more physiologically relevant microenvironment to evaluate metastasis and therapeutic response. The model exhibits oncogenic features such as EGFR overexpression and activation of the PI3K/AKT and MAPK pathways, making it ideal for testing compounds targeting tumor growth and survival mechanisms.

Detailed information on the validated H1703 xenograft model is available at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/h1703-xenograft-model/. The complete technical PDF describing the H1703 model is available at https://altogenlabs.com/H1703XenograftModel.pdf.



The NCI-H1975 xenograft model, developed and validated by Altogen Labs, provides a critical *in vivo* system for evaluating therapies targeting non-small cell lung cancer (NSCLC), particularly tumors with epidermal growth factor receptor (EGFR) mutations. The NCI-H1975 cell line was established from the lung tissue of a female non-smoker diagnosed with adenocarcinoma. It harbors the EGFR L858R activating mutation and the T790M resistance mutation, both of which contribute to therapeutic resistance against first-generation tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. This dual-mutation profile makes H1975 a cornerstone model in studies of third-generation EGFR inhibitors and resistance-overcoming strategies.

In Altogen Labs' validated xenograft protocol, H1975 cells are cultured to exponential growth, harvested using trypsin-EDTA, and suspended at a concentration of one million cells in 150 microliters of a 50 percent Matrigel solution. The cell suspension is injected subcutaneously into the flank of athymic BALB/c mice. Tumor development is monitored until reaching 100–150 mm³, at which point subjects are randomized into treatment cohorts. Tumor volumes and body weights are recorded throughout the study. At endpoint, tumors are excised, weighed, and preserved for histological and molecular analysis using techniques such as snap freezing, RNA stabilization, or paraffin embedding.

The H1975 xenograft model is highly suitable for investigating tumor growth inhibition, drug resistance mechanisms, and combination therapy regimens. Case studies have demonstrated its utility in testing epigenetic therapies and next-generation TKIs. One example, published in OncoTargets and Therapy, investigated the combination of azacitidine (a DNA methyltransferase inhibitor) and trichostatin A (a histone deacetylase inhibitor). This combination significantly suppressed tumor growth *in vivo* by disrupting AKT signaling and upregulating tumor suppressor genes such as TFF1 and VCAM1, leading to reduced tumorigenic potential. Additionally, the model supports investigations into mechanisms of resistance to Osimertinib and alternative targets such as p53 and IGF1R pathways.

Altogen Labs enables extensive customization of the H1975 model for preclinical drug evaluation. Study endpoints include Tumor Growth Delay (TGD), Tumor Growth Inhibition (TGI), and survival analysis. Dosing strategies are adaptable across multiple administration routes including intravenous, intratumoral, oral gavage, and intratracheal delivery. Optional assessments include immunohistochemistry, blood chemistry, lipid metabolism, fluorescence-based imaging, and metastasis studies via alternative engraftment routes. A positive control group using cyclophosphamide (50 mg/kg intramuscularly) may be included for comparative purposes.

Detailed information about the NCI-H1975 xenograft model is available at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/nci-h1975-xenograft-model/. The complete technical PDF describing the NCI-H1975 model is available at https://altogenlabs.com/H1975XenograftModel.pdf.

Characterization and Preclinical Application of the H1993 Xenograft Model in Lung Cancer Research



The H1993 xenograft model, validated by Altogen Labs, serves as a pivotal preclinical platform for investigating non-small cell lung cancer (NSCLC), particularly adenocarcinomas characterized by MET gene amplification. The NCI-H1993 cell line was established from a 47-year-old female patient diagnosed with stage 3A NSCLC. These cells exhibit epithelial morphology and harbor key oncogenic mutations, including alterations in KRAS and TP53 genes, contributing to their aggressive phenotype. Notably, MET gene dysregulation in H1993 cells enhances their proliferative and invasive capacities, rendering this model highly relevant for evaluating MET-targeted therapies and elucidating mechanisms of tumor progression and resistance.

In the validated xenograft protocol, H1993 cells are harvested during the exponential growth phase, resuspended in a serum-free medium supplemented with 50% Matrigel at a concentration of 50 × 10^6 cells/mL, and a 100 µL suspension containing 5×10^6 cells is subcutaneously implanted into the hind-flank region of immunocompromised mice. Tumor growth is monitored biweekly using digital calipers until tumors reach a volume of 50–200 mm^3, at which point subjects are randomized into control and treatment groups. Throughout the study, tumor volume, body weight, and general health are systematically recorded. Treatment responses are assessed through measurements of tumor size reduction, imaging analyses, and post-mortem histological evaluations to investigate tumor architecture, cell viability, and molecular markers associated with therapy.

The H1993 model has been instrumental in preclinical studies evaluating novel therapeutic agents. For instance, research published in Oncology Letters demonstrated that gambogic acid (GA) exhibits dose-dependent tumor growth inhibition in H1993 xenografts without significant toxicity. GA was found to downregulate phosphorylated MET (p-MET) and its downstream signaling molecules, p-AKT and p-ERK, indicating its potential as a therapeutic agent targeting MET-amplified NSCLC. Additionally, a study in Frontiers in Oncology reported that the glucocorticoid receptor agonist dexamethasone (DEX) induced G1/S cell cycle arrest in H1993 cells, leading to growth inhibition comparable to cisplatin. The combination of DEX and cisplatin exhibited superior anti-tumor activity, suggesting a synergistic effect and highlighting a novel precision medicine approach for LKB1-mutant NSCLCs.

Detailed information about the H1993 xenograft model is available at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/h1993-xenograft-model/. The complete technical PDF describing the H1993 model is available at https://altogenlabs.com/H1993XenograftModel.pdf.

Characterization and Preclinical Application of the HCC827 Xenograft Model in Lung Cancer Research



The HCC827 xenograft model, developed and validated by Altogen Labs, serves as a premier preclinical tool for investigating epidermal growth factor receptor (EGFR)-driven non-small cell lung cancer (NSCLC), particularly adenocarcinoma. The HCC827 cell line was established from a 39-year-old female patient and is characterized by an exon 19 deletion in the EGFR gene, which confers strong sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. Due to this mutation and its epithelial morphology, the HCC827 model is widely used to evaluate EGFR-targeted therapies, resistance mechanisms, and molecular drivers of lung tumor progression.

Altogen Labs offers both subcutaneous and metastatic HCC827 xenograft models. For the subcutaneous model, HCC827 cells are cultured to exponential growth, harvested, and suspended in serum-free medium with 50 percent Matrigel. A 100 microliter cell suspension containing 2 to 5 million cells is injected into the flank of immunocompromised mice. Tumor growth is monitored biweekly using digital calipers. Once tumors reach volumes of 150–200 mm^3, mice are randomized into treatment cohorts. Tumor progression, body weight, and general health are assessed throughout the study, and endpoint analysis includes histopathology, molecular profiling, and statistical comparison of treatment efficacy.

The HCC827 model has demonstrated broad utility in evaluating both monotherapies and combination strategies. One case study showed that oxymatrine significantly inhibited tumor growth by suppressing EGFR signaling, inducing G0/G1 cell cycle arrest through downregulation of Akt and cyclin D1. Another study using the antisense oligonucleotide EZN-3920 showed potent inhibition of HER3 and AKT signaling, enhancing the efficacy of EGFR inhibitors and overcoming resistance in HCC827 models. These results highlight the model's value in dissecting resistance pathways and developing next-generation therapeutics for EGFR-mutant NSCLC.

In addition to subcutaneous applications, Altogen Labs offers metastatic HCC827 models, established through intravenous injection to facilitate systemic tumor spread. These models allow for the study of metastatic dissemination, particularly to the lungs, liver, and lymph nodes. Real-time tumor tracking using bioluminescence or MRI is available, and endpoint analyses can include immunohistochemistry, angiogenesis profiling, and survival assessments. Researchers may evaluate therapies administered via oral gavage, intravenous, intraperitoneal, or intratumoral routes. The model is particularly well suited for assessing EGFR-targeted therapies, combination treatments, and the biological effects of resistance-inducing mutations such as T790M.

The HCC827 xenograft model is available through Altogen Labs for advanced oncology research. Complete technical information for the HCC827 can be accessed at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/hcc827-xenograft-model/. The complete technical PDF describing the HCC827 model is available at https://altogenlabs.com/HCC827XenograftModel.pdf.

Characterization and Preclinical Application of the LL/2 Xenograft Model in Lung Cancer Research



The LL/2 allograft model, developed and validated by Altogen Labs, is a syngeneic murine model widely employed in preclinical studies of lung cancer, with particular emphasis on immuno-oncology and tumor microenvironment dynamics. Derived from a spontaneous lung tumor in a C57BL/6 mouse, the LL/2 (Lewis lung carcinoma) cell line exhibits rapid proliferation, high tumorigenicity, and the capacity to form both primary and metastatic lesions. These characteristics, along with a mutational profile that includes KRAS, NRAS, Trp53, Cdkn2a, and Cdkn2b alterations, make the LL/2 model a biologically relevant system for evaluating therapeutic efficacy, tumor immunity, and resistance mechanisms.

At Altogen Labs, the LL/2 allograft model is offered in both subcutaneous and orthotopic formats. For the subcutaneous model, one million viable LL/2 cells are suspended in Matrigel and injected into the flanks of syngeneic C57BL/6 mice. Tumor development is monitored using digital calipers, and test agents are administered once tumors reach 50–150 mm³. Body weights are recorded regularly, and upon reaching endpoint criteria, tumors are excised, weighed, imaged, and preserved for downstream analyses including immunohistochemistry, histopathology, and genomic profiling. The orthotopic model involves direct lung implantation, facilitating the study of tumor-stroma interactions, spontaneous metastasis, and therapeutic responses in a more physiologically relevant setting.

The LL/2 model is particularly effective for immunotherapy evaluation due to its syngeneic nature and intact host immune system. A study by Cheng et al. demonstrated the role of CXCR2 in promoting tumor progression and resistance to chemotherapy in LL/2 models. Inhibition of CXCR2 reduced neutrophil infiltration, enhanced CD8+ T cell activity, and synergized with cisplatin to suppress tumor growth. However, LL/2 cells exhibit limited responsiveness to checkpoint blockade, making them less suitable for studies focused solely on immune checkpoint inhibition. Despite this, their robust tumorigenicity and genomic instability enable valuable assessments of combined therapeutic strategies and chemoresistance.

Additional strengths of the LL/2 model include its high vascularization, metastatic potential to lungs and lymph nodes, and responsiveness to various cytokines and chemokines. Whole-exome sequencing revealed over 20,000 somatic mutations, confirming its status as a hypermutated model that shares key genomic similarities with human lung adenocarcinoma. Altogen Labs supports extensive experimental customization including tumor growth inhibition (TGI), tumor growth delay (TGD), and survival endpoints. Dosing options include intravenous, oral, subcutaneous, intratracheal, intranasal, and continuous infusion. Advanced techniques such as microinjection, whole-body imaging, and blood chemistry analysis are also available.

Further details on the LL/2 allograft model can be found at https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/ll2-xenograft-model/. The complete technical PDF describing the LL/2 model is available at https://altogenlabs.com/LL2XenograftModel.pdf.

Preclinical Oncology Research Using Validated Lung Cancer Models from Altogen Labs

Altogen Labs provides a comprehensive portfolio of validated xenograft and allograft models that enable the preclinical evaluation of therapeutic agents across a broad spectrum of lung cancer subtypes, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and small cell lung cancer. By leveraging cell lines such as A549, H1993, H1975, HCC827, Calu-3, Calu-6, NCI-H226, NCI-H460, NCI-H1155, H526, H1703, DMS273, and the syngeneic LL/2 model, Altogen Labs supports translational oncology research from early-stage proof-of-concept through IND-enabling studies. These models replicate key histopathological and molecular characteristics of human tumors, enabling precise assessments of tumor progression, therapeutic efficacy, and resistance mechanisms.

Each model offered by Altogen Labs is supported by rigorous quality control and standardized protocols to ensure reproducibility and relevance. Xenograft models are conducted using immunocompromised mice, while syngeneic models, such as LL/2 in C57BL/6 mice, enable the study of immune-mediated responses. Experimental capabilities include subcutaneous, orthotopic, and metastatic tumor implantation, along with flexible dosing strategies through intravenous, oral, intraperitoneal, intratracheal, and intratumoral administration routes. Tumor response is monitored through caliper measurements, advanced imaging, and endpoint analyses such as immunohistochemistry, histopathology, genomic profiling, and molecular biomarker evaluation.

Altogen Labs also offers specialized services that support a wide range of oncology studies. These include tumor growth inhibition (TGI) and tumor growth delay (TGD) assessments, survival analysis, toxicity studies, ADME evaluations, and custom biomarker discovery. Fluorescence-based imaging, lipid metabolism profiling, cytokine response monitoring, and detailed necropsy procedures are also available. Altogen Labs routinely includes positive control treatment groups, such as cyclophosphamide, to benchmark novel compounds against established standards. All studies are conducted under stringent IACUC-approved protocols to ensure ethical research practices and scientific integrity.

With a strong foundation in translational oncology and a commitment to scientific excellence, Altogen Labs serves as a trusted partner to pharmaceutical and biotechnology companies advancing anticancer drug development. The availability of fully characterized, in-house validated lung cancer models, along with a team of experienced researchers and comprehensive technical capabilities, enables Altogen Labs to support the design and execution of robust preclinical studies. Additional details regarding specific xenograft models, study designs, and technical resources can be found on the Altogen Labs website.